Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Greg Yothers

Showing results (71-80 of 115) with videos related to

Pageof 12
Sort By:
Journal of the National Cancer Institute|January 15, 2010
National Institutes of Health State-of-the-Science Conference statement: Diagnosis and Management of Ductal Carcinoma In Situ September 22-24, 2009Carmen J Allegra, Denise R Aberle, Pamela Ganschow, et al.
Journal of Geriatric Oncology|July 30, 2016
Validity of Adjuvant! Online in older patients with stage III colon cancer based on 2967 patients from the ACCENT databaseDemetris Papamichael, Lindsay A Renfro, Christiana Matthaiou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2005
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31Elizabeth Tan-Chiu, Greg Yothers, Edward Romond, et al.
NIH Consensus and State-Of-The-Science Statements|September 29, 2009
NIH state-of-the-science conference statement: diagnosis and management of ductal carcinoma in situ (DCIS)Carmen J Allegra, Denise R Aberle, Pamela Ganschow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 4, 2024
Assessment of the Addition of Oxaliplatin to Fluoropyrimidine-Based Adjuvant Chemotherapy in Patients With High-Risk Stage II Colon Cancer: An ACCENT Pooled AnalysisBenoist Chibaudel, Morteza Raeisi, Romain Cohen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 6, 2009
Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancerCarmen J Allegra, Greg Yothers, Michael J O'Connell, et al.
Annals of Surgery|March 28, 2014
Comparative effectiveness of sphincter-sparing surgery versus abdominoperineal resection in rectal cancer: patient-reported outcomes in National Surgical Adjuvant Breast and Bowel Project randomized trial R-04Marcia M Russell, Patricia A Ganz, Samia Lopa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2006
Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06Barry C Lembersky, H Samuel Wieand, Nicholas J Petrelli, et al.
The New England Journal of Medicine|January 21, 2016
CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon CancerPiero Dalerba, Debashis Sahoo, Soonmyung Paik, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2009
Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data setAimery de Gramont, Joleen Hubbard, Qian Shi, et al.
Pageof 12

Showing results (71-80 of 115) with videos related to

Sort By:
Pageof 12
Journal of the National Cancer Institute|January 15, 2010
National Institutes of Health State-of-the-Science Conference statement: Diagnosis and Management of Ductal Carcinoma In Situ September 22-24, 2009Carmen J Allegra, Denise R Aberle, Pamela Ganschow, et al.
Journal of Geriatric Oncology|July 30, 2016
Validity of Adjuvant! Online in older patients with stage III colon cancer based on 2967 patients from the ACCENT databaseDemetris Papamichael, Lindsay A Renfro, Christiana Matthaiou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2005
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31Elizabeth Tan-Chiu, Greg Yothers, Edward Romond, et al.
NIH Consensus and State-Of-The-Science Statements|September 29, 2009
NIH state-of-the-science conference statement: diagnosis and management of ductal carcinoma in situ (DCIS)Carmen J Allegra, Denise R Aberle, Pamela Ganschow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 4, 2024
Assessment of the Addition of Oxaliplatin to Fluoropyrimidine-Based Adjuvant Chemotherapy in Patients With High-Risk Stage II Colon Cancer: An ACCENT Pooled AnalysisBenoist Chibaudel, Morteza Raeisi, Romain Cohen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 6, 2009
Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancerCarmen J Allegra, Greg Yothers, Michael J O'Connell, et al.
Annals of Surgery|March 28, 2014
Comparative effectiveness of sphincter-sparing surgery versus abdominoperineal resection in rectal cancer: patient-reported outcomes in National Surgical Adjuvant Breast and Bowel Project randomized trial R-04Marcia M Russell, Patricia A Ganz, Samia Lopa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2006
Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06Barry C Lembersky, H Samuel Wieand, Nicholas J Petrelli, et al.
The New England Journal of Medicine|January 21, 2016
CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon CancerPiero Dalerba, Debashis Sahoo, Soonmyung Paik, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2009
Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data setAimery de Gramont, Joleen Hubbard, Qian Shi, et al.
Pageof 12